Drug profile · INN
theophylline
NUELIN
theophylline (NUELIN) is a phosphodiesterase 4 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — theophylline
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 2
- Programs
- 4
- Data quality
- 0.89
Quick answer
theophylline (NUELIN) is a phosphodiesterase 4 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: Adenosine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is theophylline?
theophylline (NUELIN) is a phosphodiesterase 4 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for theophylline?
NUELIN is a marketed brand name for theophylline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of theophylline?
theophylline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.